Brief: Veracyte Says Decipher Prostate Test Predicts Chemotherapy Benefit In Patients With Metastatic Prostate Cancer
15/09/2024 13:58
Sept 15 (Reuters) - Veracyte Inc VCYT.O :
* VERACYTE INC - DECIPHER PROSTATE TEST PREDICTS
CHEMOTHERAPY
BENEFIT IN PATIENTS WITH METASTATIC PROSTATE CANCER
* VERACYTE INC - DATA SUPPORT COMPANY'S PLAN TO EXPAND
DECIPHER
PROSTATE TEST TO PATIENTS WITH METASTATIC DISEASE
Source text for Eikon: ID:nBwbv2ylma
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina